老年晚期肺癌高凝状态患者外周血VEGF、MMP-9的表达
Expression of Serum VEGF, MMP-9 in Eldly Patients with Advanced NSCLC in Hypercoagulative State
-
摘要: 目的 研究老年晚期高凝状态肺癌患者外周血中血管内皮生长因子 (VEGF) 与基质金属蛋白酶-9 (MMP-9) 的表达情况.方法 采用ELISA法检测VEGF、MMP-9在30例老年晚期高凝状态肺癌和30例无高凝状态的老年晚期肺癌患者血清中的表达水平.结果 老年晚期高凝状态肺癌患者外周血VEGF、MMP-9的表达水平分别为 (536±103) pg/m L、 (474±76) ng/m L, 均明显高于无高凝状态的老年晚期肺癌 (433±74) pg/m L、 (362±43) ng/m L, (P<0.05) , 且在老年晚期高凝状态肺癌外周血中VEGF水平与MMP-9的表达存在正相关关系 (r=0.478) , P<0.05, 并其高表达与患者的年龄、临床分期及伴发疾病的数量相关 (P<0.05) .结论 VEGF、MMP-9在老年晚期高凝状态肺癌外周血中高表达, 进一步证实血液高凝状态在一定程度上促进老年晚期肺癌的侵袭转移.
-
关键词:
- 老年晚期肺癌高凝状态 /
- 血管内皮生长因子 /
- 基质金属蛋白酶-9
Abstract: Objective To investigate the expression and significance of serum VEGF (vascular endothelial growth factor) and MMP-9 (matrix metalloprotoinase-9) in eldly patients with advanced NSCLC (non-small cell lung cancer) in hypercoagulative state.Methods Serum VEGF and MMP-9 were detected separately by ELISA (enzyme-linked immunosorbent assay) in 30 specimens of the eldly advanced NSCLC patients with hypercoagulative state and without hypercoagulative state.Results The expression level serum VEGF and MMP-9 was 536±103pg/m L and 474±76 ng/m L in the eldly advanced NSCLC patients with hypercoagulative state;which were higher than that in without hypercoagulative samples (433±74 pg/m L and 362±43 ng/m L) (P<0.05) .The higher expression of serum VEGF in the elder advanced NSCLC patients with hypercoagulative was positively correlated with the higher expression of MMP-9 (r=0.478) P<0.05, and which was correlated with the age, the clinical TNM stage and the number of accompanying disease (P<0.05) .Conclusion VEGF and MMP-9 are highly expressed in the eldly advanced NSCLC patients in hypercoagulative state, further confirming that hypercoagulative states to some extent may promote the invasion and metastasis of elderly patients with advanced lung cancer. -
[1] [1]FOLSOM A R, ALEKSIC N, PARK E, et al.Prospective study of fibrinolytic factors and incident coronary heart disease.The atherosclerosis risk in communities (ARIC) study[J].Arterioscler Thromb Vasc Biol, 2001, 21 (4) :611-617. [2] [2]AHMAD S, ANSARI A A.Therapeutic roles of heparin anticoagulants in cancer and related disorders[J].Med Chem, 2011, 7 (5) :504-506. [3]陈兴国, 徐海伟, 张临泉, 等.部分恶性肿瘤患者凝血功能的改变与意义[J].检验医学与临床, 2011, 16 (8) :1933-1934. [4] [4]CONNOLLY G C, PHIPPS R P, FRANCIS C W, et al.Platelets and cancer-associated thrombosis[J].Semin Oncol, 2014, 41 (3) :308-310. [5] [5]HU C, CHEN R, CHEN W.Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer[J].Exp Ther Med, 2014, 8 (1) :125-132. [6]张用, 毕建平, 皮国良, 等.国际肺癌研究协会第八版国际肺癌TNM分期修订稿解读[J].肿瘤防治与研究, 2016, 43 (4) :315. [7] [7]SPEK C A, VERSTEEG H H, BORENSZTAJN K S, et al.Anticoagulant therapy of cancer patients:Will patient selection increase overall survival[J].Thromb Haemost, 2015, 114 (3) :530-531. [8] [8]YAMASHITA Y.Hypercoagulable State in Cancer[J].Rinsho Byori, 2015, 63 (12) :1435-1442. [9] [9]LEE A Y, KAMPHUISEN P W, MEYER G, et al.Prevention of deep vein thrombosis in cancer patients[J].Semin Thromb Hemost, 2007, 33 (7) :699-706. [10] [10]LEE A Y.Treatment of venous thromboembolism in cancer patients[J].Best Pract Res Clin Haematol, 2009, 22 (1) :93-101. [11] [11]FALANGA A, SCHIEPPATI F, RUSSO D, et al.Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer[J].Semin Thromb Hemost, 2015, 41 (7) :756-764. [12]田同德, 储真真, 陈信义.恶性肿瘤高凝状态与血瘀证相关性及中医防治对策研究[J].北京中医药, 2009, 28 (6) :425-427. [13] [13]KAWAI K, WATANABE T.Colorectal cancer and hypercoagulability[J].Surg Today, 2014, 44 (5) :797-803. [14]吴秋玲, 陆宏达, 郭继龙, 等.活血化瘀中药治疗恶性肿瘤的探讨[J].世界中西医结合杂志, 2010, 5 (6) :530-531. [15] [15]RIEDL J, PABINGER I, AY C, et al.Platelets in cancer and thrombosis[J].Hamostaseologie, 2014, 34 (1) :54-62. [16] [16]ZHAO X L, SUN T, CHE N, et al.Promotion of hepaocellular carcimoma metastasis through metalloproteninase activation by epithelial-mesenchymal transition regulator Twist[J].J Cell Mol Med, 2011, 15 (3) 691-700. [17] [17]ZHANG Y, WU J Z, ZHANG J Y, et al.Detection of circulating vascular endothelial growth factor and matrix metalloproteinase-9 in non-small cell lung cancer using Luminex multiplex technology[J].Oncol Lett, 2014, 7 (2) :499-506. [18] [18]SAISHO S, YASUDA K, MAEDA A, et al.Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy[J].Interact Cardiovasc Thorac Surg, 2013, 16 (2) :166-172. [19]苟小丽, 邢时云, 杨卫兵.联合检测外周血CEA、CA125、VEGF、MT及MMP-9在晚期非小细胞肺癌表达的相关性[J].遵义医学院学报, 2014, 37 (2) :204-207. [20]张慧颖, 高全立.晚期非鳞非小细胞肺癌治疗新进展[J].中国实用医刊, 2014, 41 (11) :79-82. [21] [21]OHTA Y, WATANABE Y, TABATA T, et al.Inhibition of Lymp Hnode Metastasis by an Antiangiogenic Agent, TNP2470[J].Br J Cancer, 2007, 75 (4) :5-12. [22] [22]WANG J, ZHU C.Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients:evidence and hypothesis[J].Onco Targets Ther, 2016, 9 (9) :4737-4746.
点击查看大图
计量
- 文章访问数: 2134
- HTML全文浏览量: 770
- PDF下载量: 71
- 被引次数: 0